ABSTRACT
Background Difficulty in the diagnosis of high stress and depression has been recognized conventionally depending on the observation of patient symptoms and psychiatrist diagnosis. These approaches are time-consuming and cannot respond to the excessive demands for large-scale tests with the increasing populations worldwide. This study thus developed an alternative approach to perform fast stress screening, which is based on fingerprinting of highly volatile compounds in axillary sweat.
Methods Sweat samples were collected from 227 firefighters, comprising 65 with high stress, 14 with depression, and 148 healthy volunteers. High stress and depression were determined using the standardized Thai versions of the Perceived Stress Scale (PSS-10) and the Beck Depression Inventory II (BDI-II), in conjunction with psychiatric interviews. The samples were collected by placing cotton rods under the axillaries, then analyzed using gas chromatography– ion mobility spectrometry (GC-IMS). The potential marker peaks were selected based on accuracy data. Principal component analysis (PCA) and logistic regression with machine learning were also performed to select significant composite markers. MVOC 3.0, Amibase and Metaboanalyst 6.0 databases were applied to predict the possible metabolomic pathways.
Results Analysis against genuine standard compound injections identified acetonitrile, ammonia, diethyl ether, formaldehyde, and octane as potential biomarkers for both high stress and depression, with butane, dimethylamine and pentane additionally observed for high stress. Receiver operating characteristic (ROC) curves demonstrated accuracies of 81.3% for stress screening and 82.8% for depression screening.
Conclusion The biomarkers delineated here indicate the participation of particular metabolic pathways and commensal skin bacteria in the stress response.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Medical Council of Thailand (Grant No. 012/1621), the Second Century Fund (C2F), Chulalongkorn University and Maha Chakri Sirindhorn Clinical Research Center Under the Royal Patronage, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University gave ethical approval for this work (IRB No. 931/64).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
